BiotechTube
GeneProof

GeneProof

Brno, Czech Republic· Est.
geneproof.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

GeneProof is a Brno-based molecular diagnostics company with a comprehensive portfolio focused on infectious diseases (bloodborne, respiratory, STIs, neuroinfections) and genetic conditions like thrombotic mutations. Its core offerings include PCR test kits, extraction reagents, and the myCROBE™ fully automated system, all designed for clinical laboratory use. The 2022 merger with ALPCO significantly expanded its global commercial reach and operational scale, positioning it as a competitive player in the IVD market with a strong emphasis on regulatory compliance (IVDR). The company targets healthcare professionals through a worldwide distributor network.

Infectious DiseasesGenetic Disorders

Technology Platform

Real-time PCR (Polymerase Chain Reaction) based molecular diagnostics, including assay kits, nucleic acid extraction reagents, open-platform PCR instruments (croGENE), and the fully automated, sample-to-answer myCROBE™ system.

Opportunities

The merger with ALPCO provides immediate global commercial scale and distribution.
The stringent EU IVDR regulation creates a barrier to entry that benefits compliant companies like GeneProof, allowing it to capture market share.
The growing demand for laboratory automation and syndromic infectious disease panels aligns perfectly with GeneProof's myCROBE™ system and PCR kit portfolio.

Risk Factors

GeneProof faces intense competition from large, well-capitalized global diagnostics corporations.
Successfully integrating operations and culture with ALPCO post-merger is a critical execution risk.
Navigating diverse regulatory (e.g., FDA) and reimbursement landscapes in new global markets presents ongoing challenges.

Competitive Landscape

GeneProof competes in the crowded molecular diagnostics market against major multinationals like Roche, Abbott, bioMérieux, Qiagen, and Hologic, as well as numerous specialized players. Its differentiation is based on a focused portfolio of IVDR-compliant PCR tests, a proprietary automated system (myCROBE™), and the combined commercial strength of its merger with ALPCO.

More companies in Diagnostics & Precision Medicine →More companies in Czech Republic →